These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12572300)

  • 1. [Coxiber and risk of myocardial infarction--the apprehension might have been exaggerated].
    Oliw E; Aly A
    Lakartidningen; 2002 Dec; 99(50):5082-4, 5087. PubMed ID: 12572300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. At-risk patients still predisposed for myocardial infarction by coxibs.
    Helin-Salmivaara A; Martikainen JE
    Eur J Clin Pharmacol; 2007 Jan; 63(1):97-8. PubMed ID: 17146657
    [No Abstract]   [Full Text] [Related]  

  • 3. COX-2 selective inhibitors in the treatment of osteoarthritis.
    Laine L; White WB; Rostom A; Hochberg M
    Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global safety of coxibs and NSAIDs.
    Pham K; Hirschberg R
    Curr Top Med Chem; 2005; 5(5):465-73. PubMed ID: 15974941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is there a future for COX-2 inhibitors?].
    Yodfat Y
    Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M; Ruschitzka F
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Do selective COX-2-inhibitors increase the risk of myocardial infarction?].
    Otterstad JE
    Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3434-5. PubMed ID: 14713991
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E
    Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit versus risk in the use of non-selective NSAIDs and selective COX-2 inhibitors.
    Aalbers J
    Cardiovasc J Afr; 2012 Jul; 23(6):356. PubMed ID: 23091830
    [No Abstract]   [Full Text] [Related]  

  • 12. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NSAIDS and the risk of myocardial infarction: do they help or harm?
    Bhatt DL
    Eur Heart J; 2006 Jul; 27(14):1635-6. PubMed ID: 16782714
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
    Fiorucci S; Santucci L; Distrutti E
    Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
    Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX 2 inhibitors may increase risk of heart attack.
    Gottlieb S
    BMJ; 2001 Sep; 323(7311):471. PubMed ID: 11532833
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal outcomes: evidence for risk reduction in patients using coxibs.
    Scheiman JM
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S518-28. PubMed ID: 12458821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.